STOCK TITAN

Enveric Biosciences, Inc. - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences, Inc. (ENVB) is a pioneering biotechnology company committed to the development of innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health conditions such as depression, anxiety, and addiction disorders. Headquartered in the United States, Enveric is at the forefront of mental health research, with a focus on non-hallucinogenic solutions.

The company's flagship program, EB-003, represents a novel approach to tackling challenging mental health disorders. Unlike traditional treatments, EB-003 promotes neuroplasticity without causing hallucinations, providing a safer and potentially more effective option for patients.

Another key project in Enveric's pipeline is EB-002, previously known as EB-373. This next-generation synthetic prodrug of psilocin is being developed to offer new hope in the treatment of psychiatric disorders. With an emphasis on rigorous scientific research and clinical trials, Enveric strives to deliver breakthrough therapies that can significantly improve patients' quality of life.

Enveric's strategic vision includes forming partnerships and collaborations to enhance its research capabilities and accelerate the development of its therapeutic programs. Highlighting its commitment to innovation, the company is also investing in cutting-edge technologies such as artificial intelligence (AI) to further its research and development efforts.

Financially, Enveric Biosciences has been transparent about its funding efforts, ensuring that it maintains a robust financial foundation to support its research initiatives. With a strong commitment to ethical practices and patient-centric solutions, Enveric is emerging as a key player in the biotech sector, focused on addressing some of the most pressing mental health challenges of our time.

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) and Aries Science & Technology announced the issuance of Patent No. 12,059,393 to Enveric's subsidiary, Akos Biosciences, for a topical product aimed at treating radiation dermatitis. This condition affects approximately two million cancer patients annually, with a market opportunity estimated at $400 million. The patent issuance follows a Licensing Agreement between Aries and Akos for the clinical development of the CBD-based lotion. Aries is forming a subsidiary to advance this opportunity, with Dr. Hari Harikumar nominated as Chairman-elect. Under the agreement terms, Enveric could receive up to $61 million in milestone payments and tiered royalties ranging from 2.5% to 10% on future sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2024 financial results and provided a corporate update. The company prioritized EB-003 as its lead development candidate, a novel non-hallucinogenic neuroplastogenic molecule for treating severe mental health disorders. Preclinical results confirmed EB-003's oral bioavailability and significant brain exposure, supporting an expedited development strategy.

Key highlights include:

  • Expanded business development activities with multiple deals in advanced stages
  • Signed licensing agreement with Aries Science & Technology for radiation dermatitis product
  • Targeting IND filing for EB-003 by Q3 2025 and first-in-human trial by end of 2025
  • Q2 2024 net loss of $1.7 million ($0.23 per share) compared to $6.40 million ($3.04 per share) in Q2 2023
  • Cash-on-hand of $3.5 million as of June 30, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced promising preclinical results for EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders without hallucinogenic effects. The study revealed good oral bioavailability and significant brain exposure in rodent models, with a brain:plasma exposure ratio of ~1.5. EB-003 also demonstrated stability against human monoamine oxidase-A (MAO-A) and in various liver microsomes, unlike DMT and similar analogs.

Based on these results, Enveric is accelerating EB-003's evaluation in animal efficacy models. The company expects to file an IND application by Q3 2025 and initiate clinical development by the end of 2025. This advancement supports Enveric's patient-centered approach, aiming to develop non-hallucinogenic treatments with favorable pharmacological properties that enhance patient adherence and reduce treatment burden.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) and Aries Science & Technology have announced a licensing agreement for the clinical development of Enveric's patented radiation dermatitis topical product. This condition affects approximately two million cancer patients annually, with a market opportunity estimated at $400 million. The agreement includes potential milestone payments of up to $61 million and tiered royalties ranging from 2.5% to 10% on future sales for Enveric. Aries has nominated Dr. Hari Harikumar as Chairman-elect of a subsidiary formed to advance this opportunity. This partnership allows Enveric to focus on neuropsychiatric indications while Aries develops the cancer support care product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences announces that the United States Patent and Trademark Office has granted Patent No. 11,945,778 for its drug candidate EB-002. This new patent expands Enveric’s intellectual property by covering methods of treatment for a broad range of brain neurological disorders including sleep disorders, depression, substance-related disorders, and headaches.

EB-002, a next-generation psilocin prodrug initially developed for neuropsychiatric disorders such as anxiety, now holds three US patents covering its compositions, formulations, and methods of treatment. CEO Joseph Tucker highlights that this enhanced patent protection will help accelerate EB-002's clinical development and broaden its applicability to a wider patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has announced that it is prioritizing the development of its novel neuroplastogenic molecule, EB-003. EB-003 is designed to treat severe mental health disorders such as depression, anxiety, and addiction without causing the hallucinogenic effects often associated with psychedelic-based treatments. The company is advancing pre-clinical development and plans to meet with the FDA for a Pre-IND discussion in early 2025. EB-003 aims to overcome key issues identified by the FDA's advisory committee regarding hallucinogenic psychedelics, such as 'expectation bias' and the need for psychotherapy co-administration. Early data shows EB-003 can bind to the 5-HT2A receptor and induce neuroplasticity without significant hallucinogenic side effects in animal models, paving the way for further human clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
none
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a company focused on developing innovative neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders, announced its participation in the 2024 BIO International Convention. The event takes place in San Diego, CA, from June 3-6, 2024. Enveric aims to engage with potential investment and development partners to explore collaborations for its promising drug candidates. CEO Joseph Tucker emphasized the significant interest from strategic partners in the pharmaceutical industry for Enveric's drug discovery assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) reported financial and corporate results for the first quarter of 2024, ending March 31. The company unveiled seven classes of novel drug candidates from its Psybrary™ and PsyAI™ platforms. A business development campaign resulted in seven non-binding term sheets with four strategic partners, potentially totaling $410 million in milestone payments plus future royalties. Enveric's lead drug candidate, EB-003, is advancing towards an IND application and Phase 1 clinical trial. Proceeds from warrant exercises and investment options raised $4.5 million. The company's net loss for Q1 2024 was $2.46 million, with cash-on-hand at $6.36 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
-
Rhea-AI Summary

Enveric Biosciences, Inc (ENVB) signed a non-binding term sheet with an undisclosed biotechnology company for the exclusive license to patented methods of treating breast and other cancers using cannabinoids in combination with chemotherapeutic drugs. The licensee will receive an exclusive global license, assume responsibility for development, and pay Enveric up to $61 million in milestones and royalties. The agreement aims to advance novel treatment regimens for cancer patients, with a potential impact on breast and other cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
none
Rhea-AI Summary
Enveric Biosciences (ENVB) provided a corporate update, highlighting the selection of lead candidate EB-003 for mental health disorders. The company advanced preclinical activities for EB-002, signed term sheets for out-licensing compounds, expanded its intellectual property portfolio, and reported financial results for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags

FAQ

What is the current stock price of Enveric Biosciences (ENVB)?

The current stock price of Enveric Biosciences (ENVB) is $0.325 as of December 20, 2024.

What is the market cap of Enveric Biosciences (ENVB)?

The market cap of Enveric Biosciences (ENVB) is approximately 3.3M.

What does Enveric Biosciences specialize in?

Enveric Biosciences specializes in developing neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders.

What is EB-003?

EB-003 is Enveric's lead program designed to promote neuroplasticity in treating mental health disorders without inducing hallucinations.

What is EB-002?

EB-002, formerly known as EB-373, is a next-generation synthetic prodrug of psilocin being developed for the treatment of psychiatric disorders.

Where is Enveric Biosciences headquartered?

Enveric Biosciences is headquartered in the United States.

How does Enveric Biosciences fund its research?

Enveric Biosciences maintains a robust financial foundation through transparent funding efforts to support its research initiatives.

Is Enveric involved in any partnerships or collaborations?

Yes, Enveric forms strategic partnerships and collaborations to enhance its research capabilities and accelerate its therapeutic programs.

How does Enveric ensure its treatments do not cause hallucinations?

Enveric focuses on non-hallucinogenic solutions, as evidenced by its lead program, EB-003, which promotes neuroplasticity without causing hallucinations.

What technologies is Enveric investing in?

Enveric is investing in cutting-edge technologies such as artificial intelligence (AI) to advance its research and development efforts.

What are the core values of Enveric Biosciences?

Enveric Biosciences is committed to ethical practices, patient-centric solutions, and innovative research to address mental health challenges.

Why is Enveric considered a key player in the biotech sector?

Enveric is emerging as a key player due to its pioneering approaches to mental health treatments and significant investments in innovative research.

Enveric Biosciences, Inc.

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

3.32M
9.59M
6.93%
7.06%
3.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NAPLES